You are viewing the site in preview mode
Skip to main content
|
Baseline characteristics
|
3-dose group (n = 27)
|
4-dose group (n = 27)
|
p-value
|
|---|
|
Age, years (mean ± SD)
|
45.8 ± 13.5
|
46.6 ± 11.0
|
0.826
|
|
Male
|
16 (59.3%)
|
16 (59.3%)
|
1.000
|
|
Risk of HIV acquisition
|
0.487
|
|
Heterosexual
|
19 (70.4%)
|
21 (77.8%)
| |
|
Homosexual (MSM)
|
7 (25.9%)
|
5 (18.5%)
| |
|
Blood transfusion
|
1 (3.7%)
|
0
| |
|
IVDU
|
0
|
1 (3.7%)
| |
|
Time since HIV diagnosis, years (mean ± SD)
|
12.4 ± 6.2
|
11.3 ± 6.4
|
0.534
|
|
Duration of cART, years (mean ± SD)
|
10.0 ± 4.8
|
9.4 ± 4.7
|
0.691
|
|
CD4+ cell count, cells/mm3 (median (IQR)
|
611 (429, 853)
|
534 (392, 829)
|
0.697
|
|
Nadir CD4+ cell count, cells/mm3 (median (IQR)
|
148 (52, 323)
|
110 (52, 228)
|
0.392
|
|
Nadir CD4+ cell count < 200 cells/mm3
|
19 (70.4%)
|
18 (66.7%)
|
0.770
|
|
Current cART active against HBV
|
27 (100%)
|
27 (100%)
| |
|
cART regimen
|
1.000
|
|
NNRTI-based
|
25 (92.6%)
|
25 (92.6%)
| |
|
PI-based
|
2 (7.4%)
|
2 (7.4%)
| |
|
NRTI/NtRTI backbone
|
1.000
|
|
TDF/FTC
|
24 (88.9%)
|
23 (85.2%)
| |
|
TDF + 3TC
|
1 (3.7%)
|
1 (3.7%)
| |
|
AZT/3TC
|
1 (3.7%)
|
2 (7.4%)
| |
|
ABC/3TC
|
1 (3.7%)
|
1 (3.7%)
| |
- 3TC lamivudine, ABC abacavir, AZT zidovudine, cART combination antiretroviral therapy, FTC emtricitabine, IQR interquartile range, IVDU intravenous drug use, MSM men who have sex with men, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NtRTI nucleotide reverse transcriptase inhibitor, PI protease inhibitor, SD standard deviation, TDF tenofovir disoproxil fumarate
